Published Aug 19, 2019

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Member News
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...

Related or similar articles

December 9, 2021

Bulfinch Leases 40,000 Square Feet to Labshares

BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News
October 31, 2018

Labshares Newton Launches Near Capacity and Announces Expansion Plans

Labshares Newton, an office and laboratory incubator for emerging biotechnology and life science companies, announced the launch of its first location in Newton.
Press Releases
April 28, 2020

Labshares Newton Awards Free Project-Based Lab Space to Three Innovative Diagnostics Companies Conducting COVID-19 Research​

Labshares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space. The companies...
Labshares News